As shown in figure 2C, D, CCL2 overexpression significantly protected the tumor cells from trastuzumab treatment, elevated the half inhibitory concentration (IC50) of trastuzumab and promoted the resistance in NCI-N87 and KATO III cells via a paracrine effect on TAMs. The gene discussed is CCL2; the disease is neoplasm.